Kalevi Kurkijarvi Sells 6,000 Shares of FibroGen Inc (NASDAQ:FGEN) Stock

Share on StockTwits

FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 6,000 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $42.69, for a total value of $256,140.00. Following the transaction, the director now owns 34,400 shares in the company, valued at approximately $1,468,536. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Monday, January 6th, Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock. The shares were sold at an average price of $42.66, for a total value of $255,960.00.
  • On Monday, December 9th, Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock. The shares were sold at an average price of $47.50, for a total value of $285,000.00.

Shares of FGEN stock opened at $45.58 on Friday. FibroGen Inc has a 1-year low of $32.33 and a 1-year high of $61.23. The stock’s 50-day moving average is $43.35 and its 200 day moving average is $42.25. The company has a market cap of $3.88 billion, a P/E ratio of 114.13 and a beta of 1.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.01 and a quick ratio of 8.95.

FGEN has been the topic of a number of recent research reports. Mizuho reaffirmed a “buy” rating and set a $72.00 price objective on shares of FibroGen in a research report on Thursday. ValuEngine raised FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Zacks Investment Research downgraded FibroGen from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $51.25.

A number of hedge funds have recently modified their holdings of FGEN. FMR LLC boosted its holdings in FibroGen by 8.1% in the fourth quarter. FMR LLC now owns 9,434,188 shares of the biopharmaceutical company’s stock worth $404,632,000 after acquiring an additional 706,703 shares in the last quarter. BlackRock Inc. boosted its holdings in FibroGen by 1.0% in the second quarter. BlackRock Inc. now owns 6,233,136 shares of the biopharmaceutical company’s stock worth $281,613,000 after acquiring an additional 60,249 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in FibroGen by 35.0% in the fourth quarter. Farallon Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $57,902,000 after acquiring an additional 350,000 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in FibroGen by 21.3% in the fourth quarter. Bank of New York Mellon Corp now owns 1,142,813 shares of the biopharmaceutical company’s stock worth $49,016,000 after acquiring an additional 200,984 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in FibroGen by 20.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,453 shares of the biopharmaceutical company’s stock worth $44,968,000 after acquiring an additional 174,518 shares in the last quarter. 68.39% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Story: How does the Beige Book influence monetary policy?

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Healthcare Services Group, Inc.  Shares Acquired by Eagle Asset Management Inc.
Healthcare Services Group, Inc. Shares Acquired by Eagle Asset Management Inc.
Sherwin-Williams Co  Position Trimmed by Coastal Investment Advisors Inc.
Sherwin-Williams Co Position Trimmed by Coastal Investment Advisors Inc.
Eagle Asset Management Inc. Purchases 1,992 Shares of UMB Financial Corp
Eagle Asset Management Inc. Purchases 1,992 Shares of UMB Financial Corp
Eagle Asset Management Inc. Sells 3,193 Shares of AeroVironment, Inc.
Eagle Asset Management Inc. Sells 3,193 Shares of AeroVironment, Inc.
Coastal Investment Advisors Inc. Sells 1,728 Shares of Weyerhaeuser Co
Coastal Investment Advisors Inc. Sells 1,728 Shares of Weyerhaeuser Co
Eagle Asset Management Inc. Sells 3,592 Shares of Kornit Digital Ltd
Eagle Asset Management Inc. Sells 3,592 Shares of Kornit Digital Ltd


© 2006-2020 Ticker Report